Howard Adler, MD
Medical Oncology · Delray Beach, FLNPI 1427006782
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.2% of the total across 300 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 10.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,573 and has fallen 98.3% since, to $27 in 2025. That places this record below the midpoint for medical oncology clinicians in FL, where the typical reported total is $8,890.
Across 300 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$633
- Novartis$487
- AstraZeneca$426
- Merck$372
- Pfizer$342
- Genentech USA, Inc.$324
- plus $3K from 42 others
Across 9 payments — averaging $1689.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$14K
- Takeda Pharmaceuticals U.S.A., Inc.$709
What the payments were for
- Food & beverage$5,45393%
- Education$3987%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,851 in reported general payments places this provider in the 40th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 37 | $720,882 |
| CalquenceAcalabrutinib Maleate | 44 | $608,824 |
| ImbruvicaIbrutinib | 29 | $571,371 |
| BrukinsaZanubrutinib | 45 | $567,733 |
| VenclextaVenetoclax | 43 | $534,537 |
| Lenalidomide | 29 | $378,752 |
| JakafiRuxolitinib Phosphate | 24 | $361,777 |
| OjjaaraMomelotinib Dihydrochloride | 12 | $343,399 |
| ScemblixAsciminib Hydrochloride | 12 | $246,039 |
| BosulifBosutinib | 14 | $228,645 |
| NinlaroIxazomib Citrate | 13 | $158,542 |
| Imatinib Mesylate | 22 | $22,345 |
| XareltoRivaroxaban | 12 | $16,080 |
| Hydroxyurea | 110 | $3,127 |
| Dexamethasone | 21 | $448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $253 | $720,88237 claims |
| AstraZenecaCalquence | $426 | $608,82444 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $53 | $571,37129 claims |
| Beigene USA, Inc.Brukinsa | $41 | $567,73345 claims |
| AbbVieVenclexta | $202 | $534,53743 claims |
| Incyte CorporationJakafi | $83 | $361,77724 claims |
| GSKOjjaara | $39 | $343,39912 claims |
| NovartisScemblix | $487 | $246,03912 claims |
| PfizerBosulif | $342 | $228,64514 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $175 | $158,54213 claims |
| Johnson & JohnsonXarelto | $633 | $16,08012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Delray Beach
- Warren BrennerDelray Beach$99K
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.